Adicet Bio, Inc.
About Adicet Bio, Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$116.8M
- Total assets
- $192.4M
- Market cap
- $67.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $122.1M
- Operating income
- -$122.1M
- Income tax
- $0
- Net income
- -$116.8M
- EPS (basic)
- $-16.95
- EPS (diluted)
- $-16.95
Balance sheet
- Total assets
- $192.4M
- Current assets
- $160.9M
- Total liabilities
- $33.1M
- Current liabilities
- $21.5M
- Shareholders’ equity
- $159.2M
Cash flow
- Operating cash flow
- -$95.2M
- Investing cash flow
- $2.4M
- Financing cash flow
- $75.2M
- Net cash flow
- -$17.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $67.9M
- EPS (diluted)
- $-16.95
- Shares outstanding
- 9.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 16, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $116.8M.
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Adicet Bio, Inc..
Write a review
News about Adicet Bio, Inc.
News & sentiment via Polygon.io
